Gastric cancer is a leading cause of cancer death worldwide. Diet, obesity, smoking and
chronic infections, especially with Helicobacter pylori, contribute to stomach cancer …

HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal
junction carcinomas. In these types of cancer, accurate assessment of HER2 status is …

Introduction IMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to
Claudin-18.2, a target antigen specific to cancer cells. In vitro, IMAB362 mediates cell death …

Gastric cancer (GC) is the fifth-most common cancer worldwide and an important cause of
cancer-related-death. The growing knowledge of its molecular pathogenesis has shown that …

Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The
majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack …

Gastric cancer (GC) is the fifth most common type of cancer and the third leading cause of
cancer death in the world. It is a disease that encompasses a variety of molecular …

Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide. Recent
high-throughput analyses of genomic alterations revealed several driver genes and altered …

Gastric (including gastroesophageal junction) cancer is the third leading cause of cancer-
related death in the world. In China, an estimated 420,000 patients were diagnosed with …

Apatinib has been proved to be effective and safe among patients in gastric cancer in Phase
II and III Trials. We aimed to evaluate its efficacy and safety in real world practice, and to …

Background In China, gastric cancer (GC) ranks second in incidence and mortality. Over
80% of patients with GC were diagnosed at an advanced stage with poor clinical outcome …